Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with news of a 2021-sized biotech round that has echoes of 2011, plus an ESMO recap and a curious stock move.
The need-to-know this morning
• Novartis reported third-quarter adjusted earnings of $1.74 per share, or 3% ahead of analyst consensus. Total sales were $11.78 billion, also higher than expectations.